New arthritis drug candidate AZD6912 begins first human safety tests
NCT ID NCT06115967
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single dose of the experimental drug AZD6912 in 40 healthy adults to see if it is safe and how the body processes it. The study is a first step toward possibly treating rheumatoid arthritis, but it does not involve people with the disease. Results will help decide whether to test the drug in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD6912
What this could lead to
If this drug is safe, it could lead to a new treatment option for rheumatoid arthritis.
What could go wrong
This is a very early Phase 1 trial in only 40 healthy people, not patients. It only tests safety and dosing, not whether the drug works for arthritis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Montreal, Quebec, H3P 3P1, Canada
-
Research Site
Harrow, HA1 3UJ, United Kingdom